1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
KAINOS Laboratories, Inc.

KAINOS Laboratories, Inc.

4556.T
KAINOS Laboratories, Inc.JP flagTokyo Stock Exchange
2,268.00
JPY
- -
- -
10.10BMarket Cap

Total Valuation

KAINOS Laboratories, Inc. carries a market capitalization of 10.10B, placing it among publicly traded companies globally. Its enterprise value stands at 2.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap10.10B
Enterprise Value2.30B

Share Statistics

KAINOS Laboratories, Inc. currently has 4.22M shares outstanding.

Shares Outstanding4.22M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

KAINOS Laboratories, Inc. trades at a trailing price-to-earnings ratio of 18.13. The price-to-sales ratio is 1.89, and the price-to-book ratio stands at 0.85.

PE Ratio18.13
PS Ratio1.89
PB Ratio0.85
P/TBV Ratio0.75
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, KAINOS Laboratories, Inc. trades at an EV/EBITDA multiple of 6.61 and an EV/FCF ratio of 994.39. The EV/Sales ratio of 0.89 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 6.61 provides insight into valuation relative to core operating earnings.

EV / Sales0.89
EV / EBITDA6.61
EV / EBIT6.61
EV / FCF994.39

Financial Position

KAINOS Laboratories, Inc. maintains a current ratio of 3.66, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.51, indicating elevated leverage, while an interest coverage ratio of 100.41 demonstrates strong ability to service its debt obligations.

Current Ratio3.66
Quick Ratio2.06
Debt / Equity8.51
Debt / EBITDA1.58
Interest Coverage100.41

Financial Efficiency

KAINOS Laboratories, Inc. posts a return on equity of 4.92 and a return on invested capital of 3.30.

Return on Equity (ROE)4.92
Return on Assets (ROA)3.23
Return on Invested Capital (ROIC)3.30
Return on Capital Employed (ROCE)4.42
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.64

Taxes

Over the trailing twelve months, KAINOS Laboratories, Inc. has paid 133.75M in income taxes, reflecting an effective tax rate of 33.30.

Income Tax133.75M
Effective Tax Rate33.30

Stock Price Statistics

KAINOS Laboratories, Inc.'s stock has gained approximately 83.94161% over the past 52 weeks. The 50-day moving average sits at 2,269.82, while the 200-day moving average is 1,719.37.

Beta (5Y)N/A
52-Week Price Change83.94161%
50-Day Moving Average2,269.82
200-Day Moving Average1,719.37
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, KAINOS Laboratories, Inc. generated 2.57B in revenue and converted that into 267.90M in net income, yielding earnings per share of 63.54. EBITDA reached 347.62M, while operating income came in at 347.62M.

Revenue2.57B
Gross Profit1.24B
Operating Income347.62M
Pretax Income401.65M
Net Income267.90M
EBITDA347.62M
EBIT347.62M
Earnings Per Share (EPS)63.54

Balance Sheet

KAINOS Laboratories, Inc. holds 3.11B in cash and equivalents against 550.00M in total debt, resulting in a net debt position of -2.56B. Total book value stands at 5.69B, with working capital of 4.01B providing operational flexibility.

Cash & Cash Equivalents3.11B
Total Debt550.00M
Net Debt-2.56B
Equity (Book Value)5.69B
Book Value Per Share1,348.77
Working Capital4.01B

Margins

KAINOS Laboratories, Inc. operates with a gross margin of 48.45, reflecting its pricing power and cost economics. The operating margin of 13.53 and net profit margin of 10.43 provide insight into operational efficiency.

Gross Margin48.45
Operating Margin13.53
Pretax Margin15.64
Profit Margin10.43
EBITDA Margin13.53

Scores

KAINOS Laboratories, Inc. posts an Altman Z-Score of 3.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.30